BioNexus Gene Lab Corp. (BGLC) Financial Ratios
9 years of historical data (2016–2024) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: 311.66
P/FCF
↓
N/A
—
5yr avg: 30573.23
P/B Ratio
↓
0.44
↓-98% vs avg
5yr avg: 19.25
30Y Low0.6·High50.8
ROE
↓
-17.8%
↑-450% vs avg
5yr avg: -3.2%
30Y Low-265%·High28%
Debt/EBITDA
↓
N/A
—
5yr avg: 0.08
30Y Low0.1·High0.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BGLC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioNexus Gene Lab Corp. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $5M | $9M | $164M | $365M | — | — | — | — | — |
| Enterprise Value | $-465880 | $822304 | $3M | $162M | $363M | — | — | — | — | — |
| P/E Ratio → | -2.29 | — | — | — | 482.45 | — | — | — | — | — |
| P/S Ratio | 0.39 | 0.52 | 0.93 | 15.03 | 27.30 | — | — | — | — | — |
| P/B Ratio | 0.44 | 0.60 | 0.95 | 24.65 | 50.81 | — | — | — | — | — |
| P/FCF | — | — | — | 330.09 | 60816.36 | — | — | — | — | — |
| P/OCF | — | — | — | 297.69 | 39825.06 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BGLC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.09 | 0.34 | 14.84 | 27.15 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | 311.66 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 343.61 | — | — | — | — | — |
| EV / FCF | — | — | — | 325.95 | 60475.14 | — | — | — | — | — |
BGLC Profitability
Margins and return-on-capital ratios measuring operating efficiency
BioNexus Gene Lab Corp. earns an operating margin of -16.5%. Operating margins have compressed from -2.7% to -16.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -17.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 13.6% | 13.6% | 13.6% | 11.5% | 16.4% | 15.1% | 44.0% | 13.5% | 73.2% | — |
| Operating Margin | -16.5% | -16.5% | -26.5% | -2.7% | 7.9% | 11.2% | -217.2% | 28.2% | -118.8% | — |
| Net Profit Margin | -16.8% | -16.8% | -26.9% | -3.3% | 5.6% | 9.6% | -194.1% | 12.5% | -114.9% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -17.8% | -17.8% | -32.2% | -5.1% | 10.9% | 28.1% | -18.6% | 3.3% | -265.2% | — |
| ROA | -14.6% | -14.6% | -26.1% | -3.9% | 7.6% | 19.3% | -17.1% | 1.8% | -19.4% | -3211.5% |
| ROIC | -29.4% | -29.4% | -45.9% | -4.5% | 17.3% | 43.9% | -31.9% | 44.9% | — | — |
| ROCE | -17.2% | -17.2% | -31.4% | -4.2% | 15.1% | 32.2% | -19.9% | 7.1% | -261.3% | — |
BGLC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $210557, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | 0.08 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | 0.07 | 0.09 | — | 0.82 | — | — |
| Net Debt / Equity | — | -0.50 | -0.60 | -0.31 | -0.29 | -0.40 | -0.69 | -0.38 | -8.87 | — |
| Net Debt / EBITDA | — | — | — | — | -1.76 | -1.94 | — | -5.74 | — | — |
| Debt / FCF | — | — | — | -4.14 | -341.22 | -20.33 | — | — | -19.79 | — |
| Interest Coverage | -74.42 | -74.42 | -186.20 | -23.33 | 81.39 | 112.60 | — | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($210557)
BGLC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BioNexus Gene Lab Corp.'s current ratio of 3.81x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.10x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 3.00x to 3.81x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.81 | 3.81 | 4.93 | 3.00 | 3.04 | 2.37 | 17.11 | 20.64 | 0.85 | 0.02 |
| Quick Ratio | 3.10 | 3.10 | 4.24 | 2.52 | 2.39 | 2.02 | 16.97 | 20.40 | 0.82 | 0.02 |
| Cash Ratio | 2.24 | 2.24 | 3.64 | 1.06 | 0.91 | 0.83 | 16.66 | 20.04 | 0.71 | 0.02 |
| Asset Turnover | — | 0.91 | 0.86 | 1.25 | 1.40 | 1.13 | 0.10 | 0.13 | 0.08 | — |
| Inventory Turnover | 5.92 | 5.92 | 7.42 | 9.89 | 7.34 | 8.22 | 9.38 | 12.00 | 0.90 | — |
| Days Sales Outstanding | — | 60.65 | 32.02 | 96.85 | 91.69 | 128.15 | 8.22 | — | — | — |
BGLC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioNexus Gene Lab Corp. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 0.2% | — | — | — | — | — |
| FCF Yield | — | — | — | 0.3% | 0.0% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $2M | $2M | $1M | $1M | $857650 | $719743 | $552802 | $621896 | $621896 |
Peer Comparison
Compare BGLC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BGLCYou | $4M | -2.3 | — | — | 13.6% | -16.5% | -17.8% | -29.4% | — |
 QDEL | $737M | -0.6 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 CLOV | $2B | -18.4 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 RNAZ | $6M | -0.2 | — | — | — | — | — | — | — |
 AEYE | $98M | -31.4 | — | — | 78.3% | -7.9% | -43.2% | -42.4% | — |
 IDXX | $44B | 42.8 | 30.9 | 42.2 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 NTRA | $28B | -127.8 | — | 252.3 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 PACB | $426M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 CERS | $523M | -31.8 | — | 61.4 | 53.5% | -17.6% | -25.6% | -19.7% | — |
 TMO | $173B | 26.2 | 18.7 | 27.5 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See BGLC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BGLC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BGLC vs QDEL
Side-by-side business, growth, and profitability comparison vs QuidelOrtho Corporation.
Start ComparisonBGLC — Frequently Asked Questions
Quick answers to the most common questions about buying BGLC stock.
What is BioNexus Gene Lab Corp.'s P/E ratio?
BioNexus Gene Lab Corp.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
What is BioNexus Gene Lab Corp.'s ROE?
BioNexus Gene Lab Corp.'s return on equity (ROE) is -17.8%. The historical average is -37.1%.
Is BGLC stock overvalued?
Based on historical data, BioNexus Gene Lab Corp. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are BioNexus Gene Lab Corp.'s profit margins?
BioNexus Gene Lab Corp. has 13.6% gross margin and -16.5% operating margin.